SAMH
OVID icon

Shanda Asset Management Holdings’s Ovid Therapeutics OVID Stock Holding History

Shanda Asset Management Holdings’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-51,100
Closed -$377K – 90
2020
Q2 		$377K Buy
+51,100
New +$239K 0.03% 82

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Shanda Asset Management Holdings's OVID Position: Q3 2020 in Review

Shanda Asset Management Holdings sold out of Ovid Therapeutics (OVID) in Q3 2020, closing a stake of 51,100 shares — an estimated $377K sold.

Shanda Asset Management Holdings first reported a position in OVID in Q2 2020 and held it in 1 quarter. The position peaked at $377K in Q2 2020. 91 funds tracked by Wall St. Rank hold OVID as of Q3 2020.

  • Shanda Asset Management Holdings reported no remaining Ovid Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Shanda Asset Management Holdings sold 51,100 Ovid Therapeutics shares in Q3 2020, an estimated $377K.
  • Shanda Asset Management Holdings first reported a position in Ovid Therapeutics in Q2 2020 and held it in 1 quarter.
  • Shanda Asset Management Holdings's Ovid Therapeutics position peaked at $377K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2020.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.